After extensive due diligence, Bold Therapeutics' BOLD-100 program was one of only four COVID-19 therapeutics programs selected by the National Research Council for development support. We're currently completing an in vivo antiviral safety and efficacy study and hope to be in the clinic in mid-2021! Meanwhile, our second clinical study of first-in-class BOLD-100 in combination with FOLFOX in the treatment of advanced GI cancers continues to actively enroll patients at six cancer hospitals across Canada.
For more information and to read the National Research Council's press release, please visit:
https://www.canada.ca/en/national-research-council/news/2020/12/national-research-council-of-canada-supports-development-of-4-covid-19-therapeutic-candidates.html